1. Home
  2. AVXL vs OBIO Comparison

AVXL vs OBIO Comparison

Compare AVXL & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

N/A

Current Price

$2.44

Market Cap

237.2M

Sector

Health Care

ML Signal

N/A

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

N/A

Current Price

$6.04

Market Cap

253.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AVXL
OBIO
Founded
2004
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
237.2M
253.9M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
AVXL
OBIO
Price
$2.44
$6.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$22.00
$14.25
AVG Volume (30 Days)
677.9K
386.0K
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.13
EPS
N/A
N/A
Revenue
N/A
$33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1169.22
52 Week Low
$2.26
$2.20
52 Week High
$10.38
$6.25

Technical Indicators

Market Signals
Indicator
AVXL
OBIO
Relative Strength Index (RSI) 38.03 67.47
Support Level $2.33 $3.87
Resistance Level $2.80 N/A
Average True Range (ATR) 0.16 0.35
MACD -0.07 0.06
Stochastic Oscillator 4.42 77.27

Price Performance

Historical Comparison
AVXL
OBIO

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: